Skip to main content
. 2020 Sep 4;7(11):ofaa404. doi: 10.1093/ofid/ofaa404

Figure 2.

Figure 2.

Cumulative incidence of postindex virologic failure for people with human immunodeficiency virus (PWH) whose regimen was maintained on protease inhibitor/ritonavir (PI/r) relative to those whose regimen was switched to dolutegravir (DTG). Peto-Prentice P = .15. CI, confidence interval; NRTIs, nucleoside reverse-transcriptase inhibitors.